PreveCeutical Medical (TSE:PREV) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Dr. Barry Ticho to its Scientific Advisory Board, leveraging his seasoned expertise in drug development and biotechnology. Dr. Ticho’s impressive career includes leadership roles at Stoke Therapeutics and contributions to companies like Verve and Moderna, marking significant advancements in treating various diseases. This strategic appointment is expected to enhance BioGene’s initiatives in developing innovative therapies.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.
